[A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient].
Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused by entecavir are headache, fatigue, dizziness, and nausea. Until now, there has been no report of peripheral neuropathy as a side effect associated with entecavir treatment. Herein, we report a case of peripheral neuropathy which probably occurred after treatment with entecavir in a hepatitis B patient. The possibility of the occurrence of this side effect should be carefully taken into consideration when a patient takes a high dose of entecavir for a long period of time or has risk factors for neuropathy at the time of initiating entecavir therapy.
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Ji Hyun
JH
Song
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Si Yeon
SY
Kim
Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Jae Kyoung
JK
Shin
Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
So Dam
SD
Hong
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Kyu Sung
KS
Rim
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Ha Na
HN
Park
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Joo Ho
JH
Lee
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Yun Bin
YB
Lee
Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Seung Hun
SH
Oh
Division of Gastroenterology and Hepatology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Seong Gyu
SG
Hwang
D000284:Administration, Oral; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging; D004359:Drug Therapy, Combination; D000068736:Duloxetine Hydrochloride / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011115:Polyneuropathies / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011239:Prednisolone / Q000627:therapeutic use; D000069583:Pregabalin / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D000998:Antiviral Agents; D005938:Glucocorticoids; D000069583:Pregabalin; C413685:entecavir; D006147:Guanine; D000068736:Duloxetine Hydrochloride; D011239:Prednisolone
Entecavir; Hepatitis B; Polyneuropathies